The outcome of older (≥60 years) AML patients is poor and novel treatments are needed. In a Phase II trial for older AML patients, low-dose (20 mg/m 2 /day x 10 days) decitabine, a DNA hypomethylating azanucleoside, produced 47% complete response rate with an excellent toxicity profile. To assess the genome-wide activity of decitabine, we profiled pre-and posttreatment (day 25/course1) methylomes of marrow samples from patients (n=16) participating in the trial using deep-sequencing analysis of methylated DNA captured by methyl-binding protein (MBD2). Decitabine significantly reduced global methylation compared to pre-treatment baseline (P=0.001). Percent marrow blasts did not correlate with global methylation levels suggesting that hypomethylation was related to the activity of decitabine rather than to a mere decrease in leukemia burden. Hypomethylation occurred predominantly in CpG islands and CpG islandassociated regions (P<0.05) A significant concentration (P≤10 -10 ) of the hypomehtylated CpG islands was found in chromosome subtelomeric regions, suggesting a differential activity of decitabine in distinct chromosome regions. Hypermethylation occurred much less frequently than hypomethylation and was associated with low CpG content regions. Decitabine-related methylation changes were concordant with those previously reported in distinct genes. In summary, our study supports the feasibility of methylome analyses as a pharmacodynamic endpoint for hypomethylating therapies.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous malignant disease characterized by the accumulation of clonal, undifferentiated hematopoietic cells in bone marrow (BM) and blood.
Despite progress made in the identification of cytogenetic and molecular genetic aberrations that aid in risk stratification and the understanding of mechanisms of leukemogenesis, the majority of adult patients with AML are not cured when treated with conventional chemotherapy.
1,2 Thus, novel therapeutic targets and approaches are needed to improve outcomes for older AML patients. 3 Epigenetic silencing of structurally normal genes involved in hematopoiesis has been reported in AML and likely contributes to leukemogenesis. 4 The addition of a methyl group to the 5′ carbon position of cytosine bases via DNA methyltransferase (DNMT) activity leads to DNA methylation and silencing of gene expression. In contrast to recurrent structural genomic changes in AML, such as loss-of-function mutations or deletions causing permanent loss of gene activity, gene silencing by DNA hypermethylation can be pharmacologically reversed 5 , thereby restoring normal patterns of hematopoietic cell differentiation, proliferation and survival.
Two azanucleoside DNMT inhibitors, azacitidine (5-azacytidine; Vidaza; Celgene, Inc.) and decitabine (5-aza-2'-deoxycytidine; Dacogen; Eisai, Inc.), are now approved in the United States for treatment of patients with myelodysplastic syndromes (MDS), a clonal myeloid disorder that may evolve into AML . These agents have also been shown to be effective in AML. In a recent study, we reported the clinical results of a 10-day induction regimen of low dose decitabine in untreated older (≥60 years) AML patients who were not candidates for or refused intensive therapy. 6 We showed that decitabine induced a complete remission (CR) rate of 47%, an overall response rate of 64%, and a median overall survival duration of approximately 1 year. This regimen was also associated with an improved toxicity profile compared to that expected in patients treated with more intense chemotherapy induction regimens (i.e.,
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From which future trials might build upon to improve current treatment outcomes in older AML patients.
In order to further optimize the therapeutic use of decitabine, however, the pharmacodynamic activity of this agent needs to be fully characterized. 4 Thus, to gain insights into the genomewide localization and extent of methylation changes induced by decitabine, we applied an approach that combined "Methylated DNA Capture" with next generation sequencing (MethylCap-seq) in pre-and post-treatment BM samples from older, AML patients treated with decitabine on our Phase II clinical trial. 6 For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
Methods

Patients and samples
This study includes patients (n=16) who presented with previously untreated AML, who were diagnosed by World Health Organization (WHO) criteria, treated with decitabine on a singlecenter Phase II protocol, and had both pre-(day 0) and post-treatment (day 25 of the first cycle) BM samples available for analysis. 6 All three of these criteria were required for inclusion in this study. Patients received decitabine at 20 mg/m 2 i.v. over 1 hour on days 1 to 10 in each 4-week cycle. CR was defined according to International Working Group (IWG) published criteria. 7 Patients included in this analysis who eventually achieved CR required more than one cycle of therapy to achieve disease remission. The study design and the results of the trial for the entire cohort of patients have been previously reported. 6 Informed written consent approved by The
Ohio State University Human Studies Committee was obtained on all subjects before study entry. All the experiments involving human subjects were conducted according to the principles expressed in the Declaration of Helsinki.
MethylCap-seq assay for measuring DNA methylation
BM mononuclear cells were procured, cryopreserved and then thawed for analysis as previously reported. 6 DNA was extracted as previously reported 8 and subjected to fragmentation using a 
Methylome analysis workflow
MethylCap-seq analysis for assessing the methylation status of distinct genome regions started with the alignment of the 36 bp reads that passed the filtering to the reference genome (hg18) using the Bowtie short read aligner. 10 The 170 bp (average enriched methylated DNA fragment size) genomic regions corresponding to each unique and non-duplicated 36 bp read aligned to hg18 were identified and all the sequences parsed into 500 bp bins. As part of the binning step, aligned reads in each bin were normalized by converting them to reads per million of uniquely aligned reads (rpm) to adjust for different total read counts per lane of the Illumina flow cell. It was expected that the higher the rpm, the higher the level of methylation in the region spanned by the bin.
Global DNA methylation comparison
As DNA methylation occurs in CpG dinucleotides and the enrichment-based MethylCap-seq method interrogates the methylome in a CpG density-dependent manner, to assess average changes in global DNA methylation pre-and post-decitabine treatment, we plotted (see Supplemental Figure 1 ) the CpG density along the entire human genome (X-axis) vs. mean rpm (Y-axis; the mean of the rpms of all bins in a given CpG density interval) and then calculated the area-under-the-curves (AUCs) for each patient sample. The AUC value for each sample then served as the global methylation indicators (GMI) for that sample. The significance of global methylation differences before and after decitabine treatment was assessed by a paired sample non-parametric test (Wilcoxon signed rank test). Similarly, the significance of global methylation differences between patients who eventually achieved CR and those who never achieved CR was assessed by a Student's t-test.
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Methylation analyses of genomic features
Genomic terms (e.g., 'genomic features') used in our data analysis workflow are summarized in Supplemental Table 1 as a glossary list. The definition for each genomic feature analyzed in this study is presented in Table 1 . Elements within each genomic feature are referred to as 'regions'.
They share the feature characteristics common to that genomic feature as described in Table 1 .
The methylation level of a particular genomic feature was calculated in pre-and post-treatment samples by summing the rpm values of all of the regions of that particular genomic feature (e.g., rpm values for all CpG islands in the genome of each sample were summed to provide the methylation level of the genomic feature called CpG islands). Comparing the mean of the rpm sums obtained from the pre-treatment samples with that obtained from the post-treatment samples, we were able to assess DNA methylation changes following decitabine treatment for each of the genomic features (using a paired Wilcoxon test and a statistical significance level of P<0.05). The levels of DNA methylation changes for each genomic feature were also compared between patients who eventually achieved CR and those who never achieved CR (using a paired Wilcoxon test and a statistical significance level of P<0.05).
Identification of methylation status of regions within genomic features
To evaluate the effect of decitabine treatment on the methylation status of regions within genomic features (e.g., RefSeq genes, promoters, or CpG islands), we defined and identified differentially methylated regions (DMRs) as those regions that showed a statistically significant difference in methylation levels (expressed as rpm) when pre-and post-treatment samples were compared using the paired Wilcoxon test with a significance cutoff at a false discovery rate of 0.05. A DMR was classified as hypomethylated when the mean of the pre-treatment rpms was higher than the mean of the post-treatment rpms, or hypermethylated where the mean of the For personal use only. on August 31, 2017. by guest www.bloodjournal.org From pre-treatment rpms was lower than the mean of the post-treatment rpms in the compared samples.
Chromosomal localization of DMRs
To investigate whether DMRs are distributed randomly or non-randomly along the chromosomes, we decided to evaluate CpG islands, a genomic feature containing high CpG density, for this localization effect. The proximity of CpG dinucleotides in this feature type 
Other Statistical Analyses
To assess the relationship of blast counts and GMI values, we first evaluated potential patterns of difference using graphical analyses given the limited sample sizes. We evaluated pre-and post-treatment sample data across all patients as well as for those who eventually achieved a For personal use only. on August 31, 2017. by guest www.bloodjournal.org From CR and those who never achieved CR, as well as those classified as "informative" vs.
"uninformative" (based on percentage blasts and/or cytogenetics). Summary statistics were used to initially assess methylation markers (e.g. GMI) and blast counts across all patients as well as by "eventual CR" status. Nonparametric tests were used in an exploratory manner to assess potentially significant relationships and trends worth pursuing in future studies. Wilcoxon signed rank tests were used to assess differences in pre-vs. post-treatment measures, Wilcoxon rank sum tests were used to assess differences in markers (e.g. baseline GMI levels) between two independent groups (CR vs. not, informative vs. uninformative), and Spearman rank correlation coefficients were used to assess relationships between two continuous measures (GMI vs. blast counts). Analyses were done across all patients as well as within subgroups as noted above. When looking at correlations between GMI and blast counts, we looked at all measures (pre-and post-treatment) as well as within each time point. In this exploratory setting where we were evaluating overall measures (GMI) and clinical measures (blasts) and outcomes (CR vs. not), significance was defined as P<0.05. More formal modeling was avoided due to the limited numbers of patients available for analysis.
0
Results
Patients' characteristics
Clinical, cytogenetic and molecular characteristics of the patients with material available for MethylCap-seq analysis are reported in Table 2 . Of the 16 patients with available pre-treatment sample and day 25 post-decitabine treatment sample, 9 eventually achieved CR and 7 did not.
It should be noted that the patients who eventually achieved CR did so after more than one cycle of treatment. Therefore, these patients presented on day 25/course 1 with persistent BM >5% leukemia blast counts and/or abnormal cytogenetics and/or abnormal blood counts (i.e., neutrophils <1000/μl and platelets <100,000/μl). In the post-treatment BM samples, the mean percentage of blasts was 20.3% for patients who eventually achieved CR (range: 0 to 45) and 42.3% for those who never achieved CR (range: 3 to 90; P=0.12). Table 3 summarizes pretreatment (day 0) and post-treatment (day 25/course 1) BM blast counts and cytogenetics.
Global DNA methylation changes
To assess global DNA methylation changes following decitabine treatment, we developed the GMI as an indicator of the level of global methylation in each patient sample (see Methods for the definition of GMI). When comparing pre-and post-treatment samples from all patients, we observed a significant decrease in the mean GMI in the post-treatment samples (fold change 1.44; P=0.001; Figure 1 ). Although the number of patients analyzed was limited, we noted that patients who eventually achieved CR had a trend for higher baseline GMI and a more pronounced decrease in post-treatment GMI compared with those who never achieved CR (see Supplemental Figure 2 ).
To address the question of whether GMI values directly correlated with BM blasts and therefore were a mere index of disease burden, we tested for correlation between GMI and % blasts 1 1 (Supplemental Figure 3) in all pre-and post-treatment samples together (r=0.14; P=0.45); separately for pre-treatment samples (r=0.053; P=0.85) and post-treatment samples (r=0.18; P=0.51); in pre-treatment (r=0.067; P=0.88) and post-treatment (r=0.19; P=0.62) samples from patients who eventually achieved CR; in pre-treatment (r=0.25; P=0.59) and post-treatment (r=0.09; P=0.85) samples from patients who never achieved CR. We found no significant correlation between blast counts and GMI in all these comparisons.
Furthermore, we identified "informative" patients as those who had persistent abnormal cytogenetics and/or significant disease (i.e. BM blast counts >20%; Table 3 ) in the posttreatment sample (n =11). For these patients, we noted that the GMI (P=0.024) and not the blast counts (P=0.23) decreased significantly at day 25 compared with pre-treatment baselines.
Taken together, these data indicate that post-treatment changes in BM blasts did not account for all the decrease in DNA methylation observed in post-treatment samples, thereby supporting that the post-treatment decreased GMI was at least partly related to the hypomethylating activity of decitabine on the BM blasts.
DNA methylation changes in distinct genomic features
Next, we asked the question of whether the hypomethylating activity of decitabine affected the whole genome or impacted only specific genomic features. To address this question we examined the methylation status of distinct genomic features as defined in Table 1 . We 
Differentially Methylated Regions (DMRs)
To further characterize how statistically significant methylation changes as a result of decitabine treatment were distributed across the genome, we identified DMRs (see Methods for definition) within each of the genomic features and the direction of their methylation changes (hypo-vs. hypermethylated). In Figure 2 , we presented the overall methylation level in each genomic feature. In Table 4 we presented the percentage of regions identified as DMRs in each genomic feature and whether the DMRs were hypomethylated or hypermethylated following decitabine treatment. When we considered all patients (Table 4) there was a striking difference between CpG island-associated genomic features (CpG islands, shores, inlands, and RefSeq geneassociated islands) and genomic features partially associated with CpG islands (promoters, miRNA-associated promoters, RefSeq genes; following our gene promoter definition listed in Table 1 , 43% of promoters overlap with CpG islands) and genomic features not associated with CpG islands (gene deserts and gene deserts). In CpG island-associated genomic features, the majority of the DMRs were hypomethylated post-decitabine treatment (range 94% to 99%). For genomic features not fully associated with CpG islands, the percentage of hypomethylated DMRs ranged from 4% to 88%; we also observed an increased number of hypermethylated (Table 4) . These results were similar to those obtained from patients who eventually achieved CR (Supplemental Table 2 ). Patients who never achieved CR had no significant changes in global methylation level after decitabine treatment and therefore no DMRs to report (Supplemental Figure 2) . These results indicate that although hypomethylated DMRs were the most common type of changes found in patients who were treated with decitabine, these seemed largely limited to CpG island-associated genomic features. The number of observed hypermethylated DMRs, though small in comparison, should be dissected in future studies for their biologic and clinical significance.
Preferential chromosome location of DMRs
Whether methylation changes associated with the pharmacologic activity of decitabine occur randomly or in specific chromosome regions is unknown. We analyzed this by identifying the localization of CpG island-associated DMRs. In our analysis, we noted that these DMRs appeared to cluster at ends of chromosomes (Figure 3 ). To assess whether this observation was simply due to a higher density of CpG islands in chromosomal ends or instead was related to a selective activity of decitabine in these chromosomal regions, we divided each chromosome into 400 kb bins and calculated the expected vs. the observed number of CpG island-associated DMRs in each of these bins. We noted that these DMRS significantly clustered (P≤0.05, Pearson's Chi Squared test) at chromosomal ends except for chromosomes 2, 3, 15, 19, and 21.
Among the CpG islands positioned close to chromosome ends, many CpG island-associated DMRs fall into the chromosome subtelomeric regions defined as the terminal 500 kb of each euchromatic chromosome arm. 11 More specifically, of the 900 CpG islands in these subtelomeric regions, 323 (36%) were DMRs. The rate of methylation events observed in these regions was significantly higher than the overall genomic rate (Chi-Squared P-value ≤ 10 -10 ).
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DNA methylation changes in specific genes post-decitabine treatment
Lastly, the effect of decitabine treatment was evaluated in genes perturbed by decitabinetreatment previously reported by other groups. We extracted from our database methylation data corresponding to three loci (CDKN2B, HIST1H2AA, and GAPDH) previously reported by Brenet et al. 12 In their study, these authors evaluated the methylation status of each locus by quantitative bisulfite-PCR in AML patients treated with decitabine-priming followed by induction chemotherapy. The authors reported CDKN2B to be methylated in a low percentage of their pre-treatment samples. In contrast, HIST1H2AA was hypermethylated in AML patients and significant post-treatment hypomethylation was observed in peripheral blood granulocytes from CR patients but not in their immature BM CD34 + mononuclear cells. GAPDH, a housekeeping gene, showed little to no methylation. In our study we were able to detect methylation in CDKN2B in all but one pre-treatment sample. Patients who eventually achieved CR showed higher pre-treatment methylation levels (mean methylation level: 1.67 rpm vs. 0.63 rpm) and more extensive post-treatment hypomethylation than patients who never achieved CR (62% vs. 38%). HIST1H2AA was found to be methylated in all pre-treatment samples. Patients who eventually achieved CR had higher pre-treatment methylation levels than patients who never achieved CR (mean methylation level: 15.1 rpm vs. 10.2 rpm) and more extensive posttreatment hypomethylation (28% vs. 3%). GAPDH showed no significant methylation changes in either group of patients. We also examined the methylation changes in 15 genes comprised in a methylation classifier predictive of overall survival reported by Figueroa et al. 13 As limited information (i.e., genomic region and methylation level) was provided for these classifier genes,
we were unable to make direct comparisons to the methylation status of the genes in our database. Nevertheless, we noted that the promoter-associated CpG islands for 7 classifier genes showed post-treatment methylation changes (hypomethylation: SMG6, SRR, E2F1, 
Discussion
Here we report genome wide methylation profiling in previously untreated older AML patients who received decitabine as a single agent. 6 To our knowledge this is the first report of genomewide assessment of methylation changes induced by decitabine utilizing a high-throughput sequencing-based approach. Although the MethylCap-seq approach used here does not provide global methylome profiling at single-base resolution, it uncovered differentially methylated features and allowed analyses that were labor-, resource-, and computationally more friendly than approaches such as whole genome bisulfite sequencing. In contrast to genes and region specific methods such as determination of LINE-1 element methylation by pyrosequencing and beads array-based methylation analyses 14 , MethylCap-seq provided detailed and unbiased information for all genomic regions, including hard to access regions such as gene deserts and Repeat-masked regions. Herein, we showed the feasibility of implementing this approach in a clinical setting by a dynamic whole genome analysis of preand post-treatment BM samples from patients treated with decitabine.
Our methylome analysis reveals several interesting and original observations. First, we demonstrated that decitabine induced significant methylation changes in post-treatment BM.
Specifically our data showed that DNA hypomethylation occurred in distinct genomic features (i.e., those associated with CpG islands). The observed methylation changes occurred in many regions within various genomic features but only a limited number of them achieved posttreatment methylation levels that were significantly different from their pre-treatment levels; we designated these regions as DMRs. The types (hypo-vs. hypermethylation) of DMRs were significantly different across various genomic features. When DMRs occurred in CpG islandassociated genomic features, they were mostly hypomethylation in nature. When DMRs occurred in non CpG-island associated genomic features, they could be either hypermethylated or hypomethylated. Furthermore, we showed that DMRs were densely congregated in the subtelomeric regions of many chromosomes. Our data suggest that DNA hypermethylation in 1 7 CpG island-associated genomic features is a target for the pharmacologic activity of decitabine and that hypomethylation of these features may be associated with mechanisms of disease remission. However, the biological implications of high levels of hypomethylation events observed in CpG island-associated genomic features, and their localization in the chromosome subtelomeric regions remain to be dissected at the mechanistic level.
Although our study reveals novel and interesting findings, we recognize that these observations require further testing and validation in larger studies before definitive conclusions can be drawn, given the limited number of patients included, the retrospective nature of our analysis, and the absence of methylation analysis from earlier post-treatment time points. Importantly, in this study CRs were not achieved after the first course of decitabine treatment (day 25 of methylation analysis) suggesting that disease was still present in patients at day 25, even in those who eventually achieved CR. As we could not directly measure DNA methylation changes in AML blasts, in order to gain insight into whether the methylation changes merely reflected a decrease in the number of blasts in post-treatment marrow compared to the pre-treatment marrow or was instead also related to the pharmacologic activity of decitabine on the leukemia cells, we investigated correlations between % blasts and GMI at diagnosis and post-treatment time points and in distinct subsets of patients. We found no significant correlation between GMI and % blasts. Indeed DNA hypomethylation occurred even in the presence of significant disease and persistent abnormal cytogenetics, thereby suggesting that the global DNA hypomethylation observed post-treatment was at least partly due to the effect of decitabine on the AML blasts. Studies such as the ongoing multi-institutional randomized Phase II trial of decitabine vs. decitabine/bortezomib in older AML patients sponsored by ALLIANCE (formerly known as CALGB) will provide a larger patient population to validate these findings.
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With regard to predicting response to decitabine, it would be interesting to assess whether previously identified gene methylation classifiers that have been shown to be predictive of overall survival in AML patients treated with chemotherapy are also predictive of clinical response in patients treated with decitabine. 13 In our study we were unable to compare directly the methylation level of the 15 genes associated with the methylation classifier for AML reported by Figueroa et al. with the methylation level of these genes in our pre-treatment samples. 13 However, we did observe more differentially methylated promoter-associated CpG islands for the 15 classifier genes as a result of decitabine treatment in patients who achieved eventual CR than in those who never achieved CR (7 vs. 1, respectively). In future studies, it would be also important to assess how pre-and post-decitabine methylation changes may be related to the mutation status of distinct genes involved in epigenetic mechanisms (i.e., DNMT3A, TET2, IDH1, IDH2 and ASXL1). These genes have been shown to impact negatively on the clinical outcome of AML patients treated with conventional chemotherapy. 8,15-20 , However, it is possible that their prognostic significance may vary in patients treated with epigenetic-targeting agents. 21 For example, we recently reported preliminary data showing that the presence of DNMT3A mutation 21 and the expression of miR-29b 6 which targets and down-regulates DNMT encodinggenes (DNMT1, DNMT3A and DNMT3B) are associated with better disease response in decitabine-treated AML patients.
In conclusion, we have successfully demonstrated the feasibility of methylome profiling of sequential AML samples, the hypomethylating activity of decitabine and the potential value of DNA hypomethylation of specific genomic features as a relevant pharmacodynamic endpoint for epigenetic-targeting therapies. Ongoing larger trials of decitabine-based regimens will provide the opportunity for further evaluation and validation of these initial results.
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